Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race.

Leger P, Chirwa S, Turner M, Richardson DM, Baker P, Leonard M, Erdem H, Olson L, Haas DW. Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race. Pharmacogenetics and genomics. 2016 Dec;26(26). 473-80. PMID: 27509478 [PubMed] PMCID: PMC5014672 NIHMSID: NIHMS802173.

Abstract

Efavirenz frequently causes central nervous system (CNS) symptoms. We evaluated genetic associations with efavirenz discontinuation for CNS symptoms within 12 months of treatment initiation.